16.02.2017
Biotest AG DE0005227235
DGAP-News: Biotest AG: EUR 64.4 million operating profit in core business of Biotest
DGAP-News: Biotest AG / Key word(s): Preliminary Results
Biotest AG: EUR 64.4 million operating profit in core business of Biotest
16.02.2017 / 10:47
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
/
PRESS RELEASE
EUR 64.4 million operating profit in core business of Biotest
Dreieich, 16 February 2017. In line with the strategic realignment Biotest
has restructured its US Therapy business. In the next years Biotest will
focus in the US primarily on the plasma collection business and extend this
business. Through the cooperation with ADMA Biologics Inc. Biotest will
have access to new special products and will hereby participate in the
business with hyperimmunoglobulins in the US. In the medium term Biotest
will distribute these products in selected markets in Europe, Middle East
and Asia.
The therapy business and the toll manufacturing outside the US as well as
the plasma collection in the US and in Europe are the core business of
Biotest and are reported as Continued Operations. These recorded an
increase in profitability and revenues compared to the previous year.
According to preliminary and unaudited figures, the Biotest Group reports
EBIT (Earnings before interest and tax) in Continued Operations in the
amount of EUR 64.4 million in the full year 2016. This represents an
increase of 72.7% compared with the previous year (FY 2015: EUR 37.3
million). Compared to the previous year revenues in Continued Operations
increased by 3.5% to EUR 553.1 million in 2016 (2015: EUR 534.6 million).
The business activities, which - in line with the strategic realignment and
the contract to sell this business signed in January - will not be
continued in future, are reported as Discontinued Operation. In this
segment revenues of EUR 57.3 million were recorded in 2016 (2015: EUR 55.0
million). Earnings before interest and tax (EBIT) of the Discontinued
Operations in the amount of EUR -84.4 million resulted mainly from
extraordinary one time effects and reduce the operating profit of the group
in 2016 (pls. ref. to Ad-hoc of 23rd Jan, 2017).
In 2015 the Biotest Group has reported earnings before interest and tax
(EBIT) of all business areas of EUR -71.8 million. Despite the positive
development of the business activities in 2016 in the Continued Operations
(EUR 64.4 million) EBIT of all business areas amounted to EUR -20.0
million. Revenues of all business areas of the Biotest Group reached EUR
610.4 million in the full year 2016 after EUR 589.6 million in 2015
(+3.5%).
The EBIT-margin in the Continued Operations increased from 7.0% in 2015 to
11.6% in 2016.
Biotest will publish final results for the Financial Year 2016 and the
annual report on March 30th, 2017.
About Biotest AG
Biotest is a provider of plasma proteins and biological drugs. With a value
added chain that extends from pre-clinical and clinical development to
worldwide sales, Biotest has specialised primarily in the areas of clinical
immunology, haematology and intensive medicine. Biotest develops and
markets immunoglobulins, coagulation factors and albumins based on human
blood plasma. These are used for diseases of the immune and haematopoietic
systems. In addition Biotest develops monoclonal antibodies in the
indications of cancer of plasma cells and systemic lupus erythematosus
which are produced by recombinant technologies. Biotest has more than 2,500
employees worldwide. The preference shares of Biotest AG are listed in the
SDAX on the Frankfurt stock exchange.
IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406
email: [email protected]
PR contact
Dirk Neumüller
phone: +49-6103-801-269
email: [email protected]
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.de
Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hanover,
Munich, Stuttgart
Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.
---------------------------------------------------------------------------
16.02.2017 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: [email protected]
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
545063 16.02.2017
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Biotest AG ISIN: DE0005227235 können Sie bei EQS abrufen
Gesundheit , 522723 , BIO3 , XETR:BIO3